Pharmacodynamic Effects of Vorapaxar in Patients With and Without Diabetes Mellitus: Results of the OPTIMUS-5 Study

Vorapaxar reduces thrombotic cardiovascular events at the expense of increased bleeding. However, the differential pharmacodynamic (PD) effects of vorapaxar according to diabetes mellitus (DM) status are unknown. Moreover, although withdrawal of aspirin has emerged as a bleeding reduction strategy,...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:JACC Basic Transl Sci
Autors principals: Franchi, Francesco, Rollini, Fabiana, Kairouz, Victor, Rivas Rios, Jose, Rivas, Andrea, Agarwal, Malhar, Briceno, Maryuri, Wali, Mustafa, Nawaz, Ahmed, Silva, Gabriel, Shaikh, Zubair, Maaliki, Naji, Been, Latonya, Piraino, Jason, Pineda, Andres M., Suryadevara, Siva, Soffer, Daniel, Zenni, Martin M., Jennings, Lisa K., Bass, Theodore A., Angiolillo, Dominick J.
Format: Artigo
Idioma:Inglês
Publicat: Elsevier 2019
Matèries:
CLINICAL RESEARCH
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6978557/
https://ncbi.nlm.nih.gov/pubmed/31998847
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.jacbts.2019.07.011
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars